



Anti-Cancer Agent “Avastin®,” Judgment of the Supreme Court regarding Patent Term Extension

TOKYO, November 17, 2015 - Chugai Pharmaceutical Co., Ltd. (Chugai) (TOKYO: 4519) announced that regarding an application for patent term extension based on a market approval with respect to one of the regimens (i.e. 7.5 mg/kg every 3 weeks or more) in colorectal cancer, which has been disputed between Genentech Inc. (Genentech), a member of the Roche group, and Japan Patent Office (JPO), the Supreme Court decided to maintain the Intellectual Property High Court Grand Panel’s case decision that the trial decision of JPO to deny the application for patent term extension should be revoked.

The examination whether the patent term extension is acceptable or not will be proceeded again by JPO in light of this decision.

Genentech is a patent holder and Chugai is the licensee of Avastin.

Chugai will continue to promote the proper use of Avastin.

The impact of the matter on our financial results is currently under scrutiny. Should any information necessary to be disclosed becomes clear in the future, it will be promptly disclosed.